Ir para o conteúdo principal

Relay Therapeutics Inc (NASDAQ: RLAY) — Perfil da empresa, notícias e dados financeiros

Logo de Relay Therapeutics Inc
RLAY Relay Therapeutics Inc
Relay Therapeutics Inc primary media
Perfil da empresa

Relay Therapeutics Inc

Relay Therapeutics (NASDAQ:RLAY) is a company focused on leveraging advances in computational and structural biology to discover and develop new therapies. It operates at the forefront of precision medicine, with projects spanning from early discovery to clinical development, primarily targeting oncology and genetic disorders. Relay Therapeutics is passionate about deploying its proprietary technology to identify and develop molecules that can modulate protein functions in a dynamic manner, aiming to tackle diseases with high unmet medical needs. Its main objectives include advancing its current pipeline of potential treatments through clinical trials, expanding its research into new therapeutic areas, and continuously improving its drug discovery platform for better efficacy and patient outcomes. Relay Therapeutics is singularly listed on the NASDAQ under the ticker symbol RLAY, indicating its firm position in the biotechnology sector and commitment to innovation in drug discovery.

Resumo

Public USParticipação acionária
2015Ano de fundação
322Funcionários
Massachusetts, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Relay Therapeutics Inc

  • Ripretinib, a tyrosine kinase inhibitor aimed at treating gastrointestinal stromal tumors.
  • FGFR2 programs, focusing on advanced and metastatic cancers with FGFR2 fusions or mutations.
  • PI3Ka inhibitor projects, targeting solid tumors with specific genetic mutations.
  • SH2-containing inositol-5'-phosphatase (SHIP2) inhibition program for metabolic disorders.
  • Protein motion inhibitors, a novel class aiming at undruggable targets across various cancers.
  • Machine learning platforms for drug discovery, enhancing the speed and efficacy of identifying therapeutic candidates.

equipe executiva do Relay Therapeutics Inc

  • Sanjiv K. PatelCEO, President & Director
  • Mark MurckoFounder & Independent Director
  • Thomas CatinazzoChief Financial Officer
  • Peter RahmerChief Corporate Development Officer
  • Donald A. BergstromPresident of Research & Development
  • Dorothee KernFounder
  • David Elliot ShawFounder
  • Matthew P. JacobsonFounder
  • Jim WattersChief Scientific Officer
  • Soo-Yeun LimSenior VP & General Counsel

Principais indicadores financeiros

Resultados divulgados pela Relay Therapeutics Inc, em USD.

Cap. de mercado
4,1 bi
Receita (TTM)
10,4 mi
P/L
—
LPA (diluído, TTM)
-1.6
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Relay Therapeutics Inc
Fim do ano fiscalReceitaResultado operacionalLucro líquido
15,4 mi-302,7 mi-276,5 mi
10 mi-372,5 mi-337,7 mi
25,5 mi-373 mi-342 mi
1,4 mi-299,3 mi-290,5 mi